Drug intelligence / Profile preview

JS208

Development stage: Unknown
Lead developer: Junshi Biosciences
Modality: Small Molecules
Administration: Oral

Overview

JS208 is an orally bioavailable small molecule inhibitor of the fibroblast growth factor receptor (FGFR) family, currently under development by Junshi Biosciences for the treatment of advanced solid tumors. FGFR signaling is involved in various cellular processes, including proliferation and survival, and its dysregulation is a known driver of oncogenesis in several cancer types. JS208 aims to inhibit these receptors to disrupt downstream signaling pathways that promote tumor growth. It is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and preliminary efficacy in patients with advanced malignancies harboring FGFR alterations.

Targets

FGFR3 (Fibroblast growth factor receptor 3)

Beyond the preview

Go deeper on JS208.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JS208.

Explore the full profile